HIV/AIDS prevention study underway in Uganda

Dakar- Senegal (PANA) -- The Pfizer Foundation has plans to fund a study in Uganda to determine which preventive measures have been most effective in curbing HIV infection.
The study will be conducted over 18 months and be done in collaboration with UNAIDS, UNICEF and the Uganda AIDS Commission, the Foundation announced Monday at the UN session on AIDS in New York.
Uganda is often cited as a leader in reducing HIV infection.
The study will identify best practices in several districts throughout the country that could be expanded within Uganda and adopted in other countries.
Hank McKinnell, president of the Pfizer Foundation and chairman and chief executive officer of Pfizer, said, "By rigorously identifying effective HIV/AIDS preventative programs in Uganda, we will be able to make these learnings available worldwide.
This approach is an outstanding example of a public/private partnership addressing a complex global health issue.
" The 315,000 US dollar-study is the second major initiative by Pfizer in Uganda in the past three weeks.
Earlier this month, the Foundation announced that it is funding construction and staffing of a sophisticated AIDS clinic in Kampala that will treat more than 50,000 patients annually and provide training to African health care professionals for the diagnosis, care and treatment of HIV/AIDS patients.
The company also announced in June that it would offer its antifungal Diflucan free to AIDS patients in the 50 least developed countries, including Uganda, as identified by the UN and WHO.

26 june 2001 14:59:00




xhtml CSS